The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Dissecting The Pseudoexfoliation Syndrome With Complementary Genetic, Proteomic And Biophysical Strategies
Funder
National Health and Medical Research Council
Funding Amount
$490,352.00
Summary
Pseudoexfoliation syndrome (PEX) is an eye condition in which flaky material deposits in the eye, greatly increasing the risk of cataract and glaucoma which can lead to blindness. PEX is also associated with heart disease, strokes and aneurysms. Cataract surgery in PEX patients has a higher rate of complications. In this project we will determine the nature of PEX material and why it forms. This knowlege will facilitate better diagnosis and treatment of PEX preventing associated blindness.
A Glint Or A Squint Should Make You Think! A Randomised, Controlled Study To Determine The Impact Of An Eye-health Awareness Program For New Parents
Funder
National Health and Medical Research Council
Funding Amount
$95,348.00
Summary
Retinoblastoma (RB) is a rare, blinding and sometimes fatal, childhood eye cancer. The earliest diagnosis affords the child the best prognosis for retaining their sight, eye or their life. This project will examine parents’ current understanding of the symptoms and signs for RB, identify barriers to early diagnosis of RB, and to develop, implement and evaluate a sustainable public health awareness program to potentially improve the timing of diagnosis and subsequent outcomes for this disease.
Translating Genetic Determinants Of Glaucoma Into Better Diagnosis And Treatment
Funder
National Health and Medical Research Council
Funding Amount
$9,466,000.00
Summary
Glaucoma is the leading cause of irreversible blindness worldwide. By 2020, it will affect 80 million people, and in Australia over the next decade, the overall cost of glaucoma will reach $4.3 billion per annum. This Program will use genetic advances to personalise treatment. Blindness will be prevented in individuals at highest risk, new ways to treat patients will be developed, and better outcomes for patients will result from less treatment and monitoring of low risk cases.
Neuro-feedback For Improved Efficacy Of Retinal Prostheses
Funder
National Health and Medical Research Council
Funding Amount
$653,655.00
Summary
Bionic eyes offer the possibility to return sight to the blind. Existing retinal implants are effective at delivering basic visual percepts, namely brief spots of light. Our team is now working on building the second generation of bionic eyes that include the ability to both stimulate the visual system (the retina) and record its response. By recording the evoked responses, we can adjust and optimize the stimulation to restore a persistent high spatial resolution sense of vision to the blind.
Young Adult Myopia: Genetic And Environmental Associations
Funder
National Health and Medical Research Council
Funding Amount
$809,271.00
Summary
Myopia affects 80% of school leavers in the cities of East Asia, 45% of Asian Australian school leavers and is probably on the rise in European Australian adolescents. Increased levels of education and lack of time outdoors are known to increase the risk of myopia. We will examine 2,000 young adults to find the genes that interact with these risk factors. In addition to confirming when these risk factors are most important, identifying molecular pathways opens the avenue of new treatments.
A System For Measurement Of Vision-specific Quality Of Life Using Item Banking And Computer Adaptive Testing (ViSBank)
Funder
National Health and Medical Research Council
Funding Amount
$831,155.00
Summary
When evaluating medical treatments, it is important to consider all effects from the patient’s perspective; their quality of life. This project utilises new technology to develop an adaptable, computerised, internet-based system to measure the effects of eye diseases and their treatments on patients’ quality of life. This system will provide for more accurate, precise and efficient measurement than existing methods.
Plasticity Of Cone Bipolar Cells In Retinas With Visual Dysfunction.
Funder
National Health and Medical Research Council
Funding Amount
$328,261.00
Summary
Advances in stem cell research and gene therapy have shown great promise in their application to eye disorders that lead to blindness. This project will examine the capacity of nerve cells in the eye to remodel in the presence of visual dysfunction and subsequent recovery after gene therapy. The results from this study will therefore benefit current approaches employed for the reestablishment of vision in eye diseases.
Neuroprotection In A Model Of Chronic Ocular Hypertension
Funder
National Health and Medical Research Council
Funding Amount
$264,221.00
Summary
Damage can occur to nervous tissues like the retina and brain when there is a reduction in the blood supply. This can occur in the eye disease, glaucoma, in which the pressure inside the eye is elevated. This serious condition often results in blindness. Much of the neuronal damage is thought to be due to the release of an excess of glutamate. Glutamate is a chemical (neurotransmitter) that nerves use to communicate with each other, but it is toxic to nerves when present at high concentrations. ....Damage can occur to nervous tissues like the retina and brain when there is a reduction in the blood supply. This can occur in the eye disease, glaucoma, in which the pressure inside the eye is elevated. This serious condition often results in blindness. Much of the neuronal damage is thought to be due to the release of an excess of glutamate. Glutamate is a chemical (neurotransmitter) that nerves use to communicate with each other, but it is toxic to nerves when present at high concentrations. This project will utilise a new model of glaucoma to investigate the mechanisms that regulate the concentration of glutamate in the retina. If these mechanisms could be made to work more efficiently, they may prevent the build-up of the glutamate and therefore prevent damage to the nerve cells. Understanding these mechanisms will aid in the development of an effective treatment to prevent visual loss in the 150,000 Australians who suffer from glaucoma.Read moreRead less
A Functional Predictive Test For Age-related Macular Degeneration
Funder
National Health and Medical Research Council
Funding Amount
$532,500.00
Summary
Age-related macular degeneration (AMD) is the leading cause of blindness in our community. It is a progressive, late onset disease affecting central vision. Signs of disease are present in 15% of the population over 50 years with severe visual loss affecting increasing numbers in each subsequent decade. By 90 years 25% of people will have lost significant vision. There is no prevention, and treatment options are limited and have little impact on the rates of blindness. AMD causes enormous person ....Age-related macular degeneration (AMD) is the leading cause of blindness in our community. It is a progressive, late onset disease affecting central vision. Signs of disease are present in 15% of the population over 50 years with severe visual loss affecting increasing numbers in each subsequent decade. By 90 years 25% of people will have lost significant vision. There is no prevention, and treatment options are limited and have little impact on the rates of blindness. AMD causes enormous personal costs and places a massive burden on health resources. The high prevalence, anticipated increase in the ageing population and the limited treatment options, highlight the urgency with which research is required. The early clinical signs of AMD are yellow deposits called drusen, in the central retina (macula) and alteration in retinal pigmentation. As AMD progresses the macula is damaged either through atrophy (holes) or by growth of blood vessels. Currently, clinically accessible information about drusen and pigmentary changes are used to grade the severity of disease and predict the risk of progression to vision loss. This at risk group is recruited into prevention and intervention studies looking for new interventions. Such scoring of clinical characteristics currently underpins all clinical trials and epidemiological research in AMD. However this scheme is not without limitations, and results in an inexact correlation between clinical appearance and risk of blindness. We believe that a test of retinal function, (ability to see in the dark, to detect a faint light), will provide a better correlation for identifying patients at high risk of vision loss. We aim to test various aspects of retinal function (in both the light and dark and for moving and stationary objects) in subjects with early clinical signs of AMD, to identify parameters that will be more sensitive and specific predictors of risk of progression to visually devastating complications of AMD.Read moreRead less
Vision problems in young children can impact on educational attainment, employment opportunities and quality of life. Although severe eye disease is recognised shortly after birth, there are no Australian population-based data on the magnitude, frequency and risk factors for conditions causing moderate or milder levels of visual impairment in one or both eyes, particularly refractive error, amblyopia and strabismus. There is widespread evidence that mild or unilateral visual impairment in young ....Vision problems in young children can impact on educational attainment, employment opportunities and quality of life. Although severe eye disease is recognised shortly after birth, there are no Australian population-based data on the magnitude, frequency and risk factors for conditions causing moderate or milder levels of visual impairment in one or both eyes, particularly refractive error, amblyopia and strabismus. There is widespread evidence that mild or unilateral visual impairment in young children is frequently unrecognised and that this can sometimes lead to important adverse health outcomes. While recent data suggests that early detection and treatment could reduce development of permanent and more severe disability in the long-term, there is no consensus that screening is cost effective. The proposed study will estimate the frequency and examine risk factors and impacts from a number of childhood vision conditions in over 4,000 children, aged 6 months to under 6 years. The population sample will be derived by performing door-to-door counts of children in a random cluster sample of census districts in the Sydney region, following letter box and media publicity. Based on similar surveys we have conducted, we expect to examine at least 75% of eligible children. They will have detailed vision and eye tests using standardised methods. We will align these to methods used in a large sister US study. The project will have sufficient power to provide accurate and reliable information about conditions affecting vision in young children. These data will inform debate and assist in designing interventions to reduce disability in children from visual impairments. The multidisciplinary team has expertise in epidemiology, paediatric eye disease and in conducting vision assessments, plus a strong track record in population-based research.Read moreRead less